Retour sur lavenir.net
   CMB.TECH 14.600 € (+0,14 %)     SOLVAY 26.160 € (+0,62 %)     BREDERODE 101.600 € (-0,20 %)     TITAN S.A. 48.400 € (+1,13 %)     CENERGY 25.640 € (+6,74 %)     D'IETEREN GROUP 172.400 € (+2,93 %)     SOFINA 229.600 € (+2,59 %)     RETAIL ESTATES 71.200 € (+1,71 %)     XIOR 27.300 € (0,00 %)     AB INBEV 72.280 € (+0,53 %)     UCB 244.600 € (+1,07 %)     ASCENCIO 50.700 € (+1,50 %)     TINC 11.960 € (+2,22 %)     KBC ANCORA 81.500 € (+2,90 %)     CAMPINE 245.000 € (+6,06 %)     SIPEF 95.600 € (+0,42 %)     BANQUP GROUP 2.300 € (-6,12 %)     AZELIS GROUP 10.230 € (-0,78 %)     ELIA GROUP 139.800 € (+1,60 %)     WDP 22.160 € (+0,64 %)     TUBIZE-FIN 212.000 € (+2,02 %)     UMICORE 26.040 € (-0,53 %)     ARGENX SE 705.800 € (+0,68 %)     EVS BROADC.EQUIPM. 31.800 € (+2,09 %)     ACKERMANS V.HAAREN 279.800 € (+2,12 %)     BPOST 1.790 € (+1,24 %)     DECEUNINCK 2.090 € (+1,46 %)     COLRUYT 33.220 € (-0,72 %)     SHURGARD 23.900 € (+2,58 %)     INCLUSIO SA/NV 17.150 € (+4,57 %)     GIMV 49.700 € (+0,40 %)     MONTEA 68.200 € (+1,79 %)     VGP 80.600 € (+0,37 %)     DEME GROUP 189.600 € (+1,39 %)     COFINIMMO 84.300 € (+0,30 %)     MELEXIS 82.950 € (+1,84 %)     SYENSQO 67.400 € (+1,35 %)     VAN DE VELDE 30.200 € (-1,63 %)     CIE BOIS SAUVAGE 320.000 € (+2,24 %)     ORANGE BELGIUM 21.500 € (0,00 %)     BIOTALYS 2.945 € (+2,26 %)     KINEPOLIS GROUP 29.700 € (+1,37 %)     LOTUS BAKERIES 10 940.000 € (+0,92 %)     BARCO 9.160 € (+0,16 %)     PROXIMUS 6.830 € (-1,01 %)     ONWARD MEDICAL 2.890 € (+2,12 %)     HOME INVEST BE. 19.300 € (+1,90 %)     AGEAS 68.650 € (+0,81 %)     BEKAERT 41.500 € (+0,12 %)     VASTNED 29.600 € (+0,34 %)     IBA 15.720 € (+2,21 %)     FAGRON 25.250 € (+1,00 %)     TESSENDERLO 21.250 € (-0,70 %)     ACCENTIS 0.027 € (+3,85 %)     GBL 81.950 € (+1,17 %)     ONTEX GROUP 2.660 € (0,00 %)     CARE PROPERTY INV. 13.240 € (+0,46 %)     IMMOBEL 21.800 € (0,00 %)     JENSEN-GROUP 77.600 € (+1,57 %)     ECONOCOM GROUP 1.510 € (-2,58 %)  
   NEXANS 162.000 € (+2,21 %)     SOITEC 176.300 € (-0,59 %)     CARREFOUR 17.115 € (+0,15 %)     REMY COINTREAU 40.280 € (-0,79 %)     AIRBUS 174.260 € (+2,80 %)     CREDIT AGRICOLE 17.450 € (+1,10 %)     SES 8.895 € (-0,61 %)     UNILEVER 49.030 € (-0,60 %)     SEMCO TECHNOLOGIES 49.400 € (+1,23 %)     CATANA GROUP 2.345 € (+2,40 %)     VICAT 64.100 € (+3,72 %)     BIOSYNEX 1.170 € (+13,04 %)     RIBER 16.280 € (+5,99 %)     HAVAS 16.850 € (+2,12 %)     SMCP 5.125 € (+1,38 %)     VERALLIA 19.860 € (-1,29 %)     DBT 0.056 € (+30,23 %)     SOCIETE GENERALE 71.900 € (+4,51 %)     REXEL 37.370 € (+1,85 %)     LHYFE 2.345 € (+0,21 %)     ASML HOLDING 1 430.600 € (+1,53 %)     CAPITAL B 0.589 € (+0,10 %)     KPN KON 4.580 € (-0,89 %)     EUROCOMMERCIAL 28.750 € (+0,70 %)     ASM INTERNATIONAL 905.000 € (+0,47 %)     EUROFINS SCIENT. 63.240 € (+1,05 %)     VEOLIA ENVIRON. 35.330 € (+1,84 %)     ARCELORMITTAL SA 58.240 € (+2,57 %)     EURONEXT 145.400 € (-0,55 %)     SANOFI 77.460 € (+0,75 %)     SAINT GOBAIN 77.500 € (+2,95 %)     DANONE 61.720 € (-0,23 %)     BNP PARIBAS ACT.A 92.520 € (+2,88 %)     MEDINCELL 26.720 € (-1,69 %)     COVIVIO 54.700 € (+2,05 %)     ASR NEDERLAND 66.480 € (+1,09 %)     PHILIPS KON 23.800 € (+1,84 %)     2CRSI 49.400 € (+5,78 %)     ADYEN 987.600 € (+3,10 %)     NEXITY 8.330 € (+2,40 %)     BAM GROEP KON 9.725 € (+6,28 %)     AIR FRANCE -KLM 10.895 € (+6,24 %)     BOUYGUES 50.280 € (+1,93 %)     WOLTERS KLUWER 61.740 € (+1,35 %)     HAL TRUST 176.600 € (+0,80 %)     PLANISWARE 18.920 € (+1,61 %)     KLEA HOLDING 0.190 € (+3,49 %)     BAINS MER MONACO 133.000 € (-1,48 %)     TIKEHAU CAPITAL 17.860 € (-0,22 %)     L'OREAL 367.650 € (+1,66 %)     CAPGEMINI 104.250 € (+1,12 %)     GECINA 72.900 € (+0,76 %)     ORANGE 18.140 € (-0,36 %)     ROCTOOL 2.040 € (+17,92 %)     BE SEMICONDUCTOR 282.000 € (+3,07 %)     LVMH 477.900 € (+1,12 %)     STMICROELECTRONICS 58.020 € (+0,16 %)     EKINOPS 3.415 € (+10,16 %)     VERIMATRIX 0.205 € (+12,64 %)     PROSUS 40.155 € (+2,80 %)  
News Réglementées
12/05/2026 07:00

MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across the U.S.

MindMaze Therapeutics Holding SA / Key word(s): Partnership
MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across the U.S.

12-May-2026 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across the U.S.

Vibra to Support Expansion of MindMaze Therapeutics’ Neurorehabilitation Platform across Leading U.S. Health Systems
 

Geneva, Switzerland and Mechanicsburg, Pennsylvania – May 12, 2026 MindMaze Therapeutics, a pioneer in advanced neurotherapeutic technologies, and Vibra Healthcare, a leading provider of neurological care and rehabilitation services, today announced the signing of a definitive channel partnership agreement. The agreement follows the previously announced term sheet and formalizes Vibra’s role as a strategic commercial partner to introduce MindMaze Therapeutics’ FDA-cleared digital neurotherapeutics platform to leading U.S. health systems.

“This next phase of our collaboration with Vibra is a significant step in MindMaze Therapeutics’ U.S. commercial expansion. Vibra has successfully implemented our platform across multiple care settings, and together we have demonstrated the results and built the operational playbook. We are now positioned to replicate that proven model with health systems across the country and further build our U.S. footprint,” said Zach Henderson, CEO of MindMaze Therapeutics.

Under the agreement, Vibra will leverage its national relationships and operational credibility to connect MindMaze Therapeutics with providers investing in advanced neurorehabilitation capabilities. The commercial model is anchored by Vibra’s own two-year, multi-site deployment of the MindMaze Therapeutics platform across five inpatient rehabilitation centers, which demonstrated that the high-dose, high-intensity therapy recommended by guidelines can be operationalized at scale without increasing staffing burden.

“Vibra entered this relationship because we saw a genuine opportunity to change what’s possible in neurorehabilitation,” said Brad Hollinger, Chairman and CEO of Vibra Healthcare. “What we’ve built with MindMaze Therapeutics is a scalable model that leading rehabilitation providers should aspire to offer. We look forward to bringing it to health system partners across the country.”

Providers adopting the platform gain a scalable solution that enables clinicians to treat more patients at a higher level of care with the same resources, supports shorter inpatient lengths of stay, improves community discharge rates, and delivers consistent therapy intensity across the full continuum of care.

MindMaze Therapeutics expects the Vibra partnership to be a key driver of new U.S. health system customer acquisition in the second half of 2026 and beyond.

About Vibra Healthcare
Vibra Healthcare, LLC is a post-acute care provider based in Mechanicsburg, Pennsylvania. Vibra Healthcare is focused on the development, acquisition, and operation of freestanding specialty acute care hospitals, medical rehabilitation hospitals, and outpatient physical rehabilitation centers. Teams of highly trained specialists lead clinical programs at Vibra’s specialty hospitals for rehabilitating patients who suffer from stroke, multiple traumas, major orthopedic, neurologic, cardiac, and respiratory conditions. Vibra and its affiliates currently employ over 4,000 employees and own, operate, and manage more than 25 specialty hospitals, transitional care facilities, and hospital-based outpatient physical therapy locations across 10 states. For additional information about Vibra Healthcare’s network of specialty hospitals and post-acute care continuum, please visit www.vibrahealthcare.com.

About MindMaze Therapeutics
MindMaze Therapeutics (SIX: MMTX) is a global leader in scalable, precision neurotherapeutics, dedicated to redefining the recovery trajectory for patients around the world. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy. The company’s FDA-cleared and CE-marked products are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson’s disease, and other neurological disorders. With an extensive library of rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine. For more information, visit www.mindmazetherapeutics.com.

Media Contacts
Jenna Fehr, Vibra Healthcare | jlescavage@vibrahealth.com
Jeremy Meinen, MindMaze Therapeutics | ir@mindmazetherapeutics.com

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


Additional features:


File: Ad hoc release_MindMaze-Vibra_Definitive Channel Partnership

End of Inside Information
Language:English
Company:MindMaze Therapeutics Holding SA
Avenue de Secheron 15
1202 Geneva
Switzerland
Phone:+41 22 545 11 16
Fax:+41 22 545 11 17
E-mail:ir@mindmazetherapeutics.com
Internet:www.mindmazetherapeutics.com
ISIN:CH1251125998
Listed:SIX Swiss Exchange
EQS News ID:2325694

 
End of AnnouncementEQS News Service

2325694  12-May-2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière